Robert E. Hoffman - 01 Aug 2022 Form 4 Insider Report for Kintara Therapeutics, Inc. (HURA)

Role
President and CEO, Director
Signature
/s/ Anthony Scott Praill, attorney-in-fact for Robert E. Hoffman
Issuer symbol
HURA
Transactions as of
01 Aug 2022
Net transactions value
$0
Form type
4
Filing time
03 Aug 2022, 16:30:30 UTC
Previous filing
17 Feb 2022
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KTRA Common Stock Award $0 +400,145 +728% $0.000000 455,145 01 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KTRA Option (right to buy) Award $0 +1,200,634 $0.000000 1,200,634 01 Aug 2022 Common Stock 1,200,634 $0.1757 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted 400,145 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.
F2 The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.